Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

New science, drug regulation, and emergent public health issues: The work of FDA’s division of applied regulatory science
Kimberly Chiu, Rebecca Racz, Keith Burkhart, et al.
Frontiers in Medicine (2023) Vol. 9
Open Access | Times Cited: 20

Showing 20 citing articles:

Organ-on-a-chip: quo vademus? Applications and regulatory status
Maria Mendes, Ana Sofia Morais, A Carlos, et al.
Colloids and Surfaces B Biointerfaces (2025) Vol. 249, pp. 114507-114507
Open Access | Times Cited: 1
Clinical trials and commercialization of endophytic fungal–derived therapeutics
Pushkar Bharti, Ankita Arora, Gurleen Kaur Sodhi, et al.
Elsevier eBooks (2025), pp. 251-276
Closed Access
Strengthening Global Health Resilience: Marburg Virus-Like Particle Vaccines and the One Health Approach
Ram Bahadur Khadka, Khimdhoj Karki, Jitendra Kumar Pandey, et al.
Science in One Health (2024) Vol. 3, pp. 100076-100076
Open Access | Times Cited: 3
The FDA’s New Guideline “Generally Accepted Scientific Knowledge” (GASK): An Opportunity to Expedite the Approval of Biosimilars
Sarfaraz K. Niazi
Pharmaceuticals (2023) Vol. 16, Iss. 11, pp. 1517-1517
Open Access | Times Cited: 7
Biosimilars in the Era of Artificial Intelligence—International Regulations and the Use in Oncological Treatments
Tomás Gabriel Bas, Vannessa Duarte
Pharmaceuticals (2024) Vol. 17, Iss. 7, pp. 925-925
Open Access | Times Cited: 2
Biosimilars Adoption: Recognizing and Removing the RoadBlocks
Sarfaraz K. Niazi
ClinicoEconomics and Outcomes Research (2023) Vol. Volume 15, pp. 281-294
Open Access | Times Cited: 5
A Critical Analysis of the FDA’s Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity
Sarfaraz K. Niazi
Pharmaceuticals (2023) Vol. 16, Iss. 11, pp. 1556-1556
Open Access | Times Cited: 5
Functional Biosimilarity to Replace Clinical Efficacy Testing of mAb Biosimilars: Advancing the FDA Perspective
Sarfaraz K. Niazi
(2023)
Open Access | Times Cited: 4
Support for Removing Pharmacodynamic and Clinical Efficacy Testing of Biosimilars: A Critical Analysis
Sarfaraz K. Niazi
Clinical Pharmacology in Drug Development (2023) Vol. 12, Iss. 12, pp. 1134-1141
Open Access | Times Cited: 4
A Dynamic Model for GMP Compliance and Regulatory Science
Yiyi Bao, Nicholas Buhay, Qiang Zheng
Journal of Pharmaceutical Innovation (2024) Vol. 19, Iss. 3
Open Access | Times Cited: 1
Why More Biologists Must Embrace Quantitative Modeling
Brook G. Milligan, Ashley T. Rohde
Integrative and Comparative Biology (2024) Vol. 64, Iss. 3, pp. 975-986
Closed Access | Times Cited: 1
Monoclonal antibody biosimilars for cancer treatment
Linda N. Broer, Daan G. Knapen, Derk‐Jan A. de Groot, et al.
iScience (2024) Vol. 27, Iss. 6, pp. 110115-110115
Open Access | Times Cited: 1
Construction, Features and Regulatory Aspects of Organ-chip for Drug Delivery Applications: Advances and Prospective
Babita Gupta, Rishabha Malviya, Saurabh Srivastava, et al.
Current Pharmaceutical Design (2024) Vol. 30, Iss. 25, pp. 1952-1965
Closed Access | Times Cited: 1
A Proposed Global Medicines Agency (GMA) to Make Biological Drugs Accessible: Starting with the League of Arab States
Sarfaraz K. Niazi
Healthcare (2023) Vol. 11, Iss. 14, pp. 2075-2075
Open Access | Times Cited: 3
Reinventing Therapeutic Proteins: Mining a Treasure of New Therapies
Sarfaraz K. Niazi, Zamara Mariam
Biologics (2023) Vol. 3, Iss. 2, pp. 72-94
Open Access | Times Cited: 2

Yesh Kumar, Mukesh Maithani, Raman Yadav
International Journal of Pharmaceutical Sciences and Research (2024) Vol. 15, Iss. 6
Open Access
A timely recommendation to the european medicines agency and the FDA on rationalizing comparative clinical efficacy testing of biosimilars
Sarfaraz K. Niazi
Deleted Journal (2024) Vol. 1, Iss. 1
Open Access
A Novel Global Medicines Agency (GMA) Formation Proposal for Making Biotechnology Drugs Affordable: Starting with the League of Arab States.
Sarfaraz K. Niazi
(2023)
Open Access | Times Cited: 1
A Critical Analysis of the FDA Omics Perspective on Pharma-codynamic Biomarkers to Support Biosimilarity, and its Surrogates.
Sarfaraz K. Niazi
(2023)
Open Access | Times Cited: 1
Ranolazine Quantification in Human Plasma: A QbD-Guided LC-MS Method Development and Validation
Jagirdar SZ Farooq, Furquan Nazimuddin Khan
International Journal of Pharmaceutical Quality Assurance (2023) Vol. 14, Iss. 04, pp. 882-887
Open Access
Page 1

Scroll to top